MetaCap

Filana Therapeutics (FLNA) vs MindWalk (HYFT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MindWalk (HYFT) has outperformed Filana Therapeutics (FLNA) over the past year, losing 59.0% versus a loss of 77.7%. Over five years, HYFT leads with a -89.3% price change compared with -98.9% for FLNA. MindWalk is the larger company by market cap ($32.6 million vs $32.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FLNA-77.66%HYFT-59.02%
+74%-9%-93%
Nov 21, 20251 yearNov 20, 2026
FLNA-98.79%HYFT-87.65%
+22%-42%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FLNA versus HYFT key metrics
MetricFLNAHYFT
Share price$0.6413$0.6844
Market cap$32.26M$32.56M
1-day change+14.52%-14.27%
YTD return-67.61%-62.40%
1-year return-77.66%-59.02%
5-year return-98.85%-89.34%
EPS (TTM)$-0.87$-0.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-90.97M—
52-week high$3.45$2.99
52-week low$0.39$0.64
Distance from 52-week high-81.41%-77.11%
Analyst consensusnonenone
Avg. price target upside+913.57%+532.67%
Average volume2.09M257.86K
Shares outstanding50.30M47.57M
Employees1774
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HYFT has outperformed FLNA by 18.6 percentage points over the past year.

About Filana Therapeutics

FLNA stock →

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About MindWalk

HYFT stock →

MindWalk Holdings Corp. operates as a bio-native AI company.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

FLNA vs HYFT FAQ

Which is bigger, Filana Therapeutics or MindWalk?

MindWalk (HYFT) is larger, with a market capitalization of $32.56M compared with $32.26M for Filana Therapeutics (FLNA).

Which stock has performed better over the past year, FLNA or HYFT?

HYFT returned -59.02% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.

Are Filana Therapeutics and MindWalk in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons